Each sustained-release tablet contains Glibenclamide 5 mg + Metformin Hydrochloride 500 mg SR.

Glutowin Forte Tablets combine the insulin-secretagogue action of glibenclamide with the insulin-sensitizing effects of metformin to provide effective glycaemic control in patients with type 2 diabetes mellitus. Glibenclamide stimulates pancreatic insulin secretion, while metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity. This dual-mechanism therapy helps improve both fasting and postprandial blood glucose levels in patients inadequately controlled with monotherapy.

Glutowin Forte Tablets are indicated for the treatment of non-insulin dependent diabetes mellitus (Type 2 Diabetes Mellitus) in patients who are inadequately controlled with sulphonylurea or biguanide monotherapy, along with appropriate diet and exercise.

Glibenclamide is a second-generation sulphonylurea that lowers blood glucose by stimulating insulin release from functional pancreatic β-cells. Metformin is an antihyperglycaemic agent that improves glucose tolerance by decreasing hepatic glucose production, reducing intestinal glucose absorption, and enhancing peripheral glucose uptake and insulin sensitivity. Together, these complementary mechanisms provide improved glycaemic control in patients with type 2 diabetes mellitus.

The recommended dosage is one tablet once daily with meals, or as directed by the treating physician. Dosage should be individualized according to the patient's glycaemic response and clinical condition.

Glutowin Forte is contraindicated in patients with hypersensitivity to glibenclamide, metformin, other sulphonylureas, sulphonamides, or any component of the formulation. It is also contraindicated in patients with type 1 diabetes mellitus, diabetic ketoacidosis (with or without coma), and acute conditions that may impair renal function, including severe infection, dehydration, or shock.